Literature DB >> 8970055

Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis.

M B Oliveri1, R Palermo, C Mautalen, O Hübscher.   

Abstract

An 8-year-old girl with juvenile dermatomyositis (DM) developed dystrophic calcifications 26 months after diagnosis. She also had severe steroid induced bone loss (osteoporosis). The calcifications turned into generalized heterotopic calcinosis with an exoskeleton-like pattern, despite successful treatment of her myopathy with methylprednisolone and immunosuppressive drugs. She was subsequently treated with oral diltiazem (5 mg/kg/day) to control calcinosis and oral pamidronate (4 mg/kg/day) in addition to calcium and vitamin D supplementation, which she had been taking for 3 years. After 21 months of treatment, clinical and radiological examination revealed dramatic regression of the calcinosis. Bone mass reached normal levels, as determined by bone absorptiometry. Diltiazem alone or in combination with other drugs could be a useful therapy in patients with juvenile DM and pronounced calcifications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970055

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 2.  Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis.

Authors:  Lauren M Pachman; Adele L Boskey
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

Review 3.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

4.  Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy.

Authors:  Hiroko Mori; Yosuke Okada; Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2011-06-28       Impact factor: 2.626

Review 5.  Juvenile dermatomyositis: recognition and treatment.

Authors:  Ann M Reed; Maricarmen Lopez
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Treatment of Calcinosis in Juvenile Dermatomyositis.

Authors:  Ovgu Kul Cinar; Charalampia Papadopoulou; Clarissa A Pilkington
Journal:  Curr Rheumatol Rep       Date:  2021-02-08       Impact factor: 4.592

Review 7.  Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors:  J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

Review 8.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

9.  [Extraosseous calcifications in dermatomyositis. A rare differential diagnosis of a benign heterotropic ossification].

Authors:  S Ochman; U Frerichmann; M Schult; R H Meffert
Journal:  Unfallchirurg       Date:  2004-04       Impact factor: 1.000

Review 10.  Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.

Authors:  Hobart W Walling; Pedram Gerami; Richard D Sontheimer
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.